Goldman Sachs upgraded China Medical System to Buy from Neutral with a price target of HK$18.88, up from HK$16.86. The firm believes the VBP uncertainty for the three core products of Deanxit, Plendil and Ursofalk is reducing and sees the company entering a new product cycle.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CHSYF: